Stockscreener 앱 받기
2.285
0.23%
-0.005
Compass Therapeutics Inc 주식(CMPX)의 최신 뉴스
CMPX Stock Has Retail Buzzing Ahead Of High-Stakes Cancer Drug Trial Update - Stocktwits
If You Invested $1,000 in Compass Therapeutics Inc (CMPX) - Stock Titan
Here’s Why Citizens Maintains a Buy on Compass Therapeutics (CMPX) - Insider Monkey
Bronstein, Gewirtz & Grossman, LLC Is Investigating Compass Thera - The National Law Review
Compass Showcases Promising Tovecimig Data, Eyes Commercialization - TipRanks
Compass updates corporate presentation, reports positive Phase 2/3 COMPANION-002 BTC data and plans BLA engagement - TradingView
Compass Therapeutics (NASDAQ: CMPX) targets BLA after biliary tract cancer trial success - Stock Titan
Compass Therapeutics (CMPX) 10K Form and Latest SEC Filings 2026 - MarketBeat
A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs - Sahm
Enterprise value to revenue forward of Compass Therapeutics, Inc. – NASDAQ:CMPX - TradingView
Price to sales forward of Compass Therapeutics, Inc. – NASDAQ:CMPX - TradingView
$Compass Therapeutics (CMPX.US)$ - Moomoo
Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell 3000 Growth Benchmark - marketscreener.com
Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell 2000 Growth Benchmark - marketscreener.com
Compass Therapeutics Inc. (CMPX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Compass Therapeutics (CMPX) Stock Forecast & Analyst Ratings - Moomoo
Compass Therapeutics, Inc. Actuals & Estimates (NASDAQ:CMPX) - TradingView
CMPX Forecast — Price Target — Prediction for 2027 - TradingView
Compass Therapeutics Inc. (CMPX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Compass Therapeutics Adopts Second Amended and Restated Bylaws - The Globe and Mail
Compass Therapeutics Inc. (CMPX) Institutional Confidence - TradingKey
Compass Therapeutics Inc. (CMPX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Compass Therapeutics Inc. (CMPX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Compass Therapeutics Inc. (CMPX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
How Compass Therapeutics (CMPX) Is Moving Tovecimig Toward a Potential Biliary Tract Cancer Filing - Insider Monkey
Compass Therapeutics Inc. (CMPX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Compass Therapeutics Inc. (CMPX) Valuation: PE, PB & Fair Value Analysis - TradingKey
5 Small Cap Stocks with Potential to Rise 1000 Percent - Insider Monkey
Compass Therapeutics eyes FDA path after Tovecimig trial win - MSN
Compass Therapeutics Shareholders Back Directors, Pay, Auditor Oversight - The Globe and Mail
Compass Therapeutics (NASDAQ: CMPX) investors back board, auditor and pay in 2026 votes - Stock Titan
CMPX: Lead oncology asset tovecimig nears FDA filing after strong BTC trial results; multiple catalysts ahead - TradingView
Compass Therapeutics, Inc. (CMPX) Latest Stock News & Headlines - Yahoo Finance
Compass Therapeutics Eyes FDA Path After Tovecimig Trial Win - MarketBeat
CMPX News | COMPASS THERAPEUTICS INC (NASDAQ:CMPX) - ChartMill
Citizens reiterates Compass Therapeutics stock rating on ASCO data By Investing.com - Investing.com Nigeria
CMPX: Lead drug tovecimig showed strong efficacy in BTC; key FDA and data milestones expected this year - TradingView
CMPX Stock Chart | COMPASS THERAPEUTICS INC (NASDAQ:CMPX) - ChartMill
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Compass Therapeutics (CMPX) and Tenax Therapeutics (TENX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Emergent Biosolutions (EBS) and Compass Therapeutics (CMPX) - The Globe and Mail
Piper Sandler Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Cuts Target Price to $4 - Moomoo
Stifel reiterates Compass Therapeutics stock rating on ASCO data By Investing.com - Investing.com Canada
Number of shareholders of Compass Therapeutics, Inc. – NASDAQ:CMPX - TradingView
CMPX Q1 2026 Earnings: Narrow EPS Beat Drives Positive Stock ReactionTrough Earnings Signal - thelegaladvocate.com
Compass Therapeutics to Participate in Upcoming June Investor Events - Investing News Network
CMPXCompass Therapeutics Inc Latest SEC Filings - Finviz
Analysts Are Bullish on These Healthcare Stocks: Fortrea Holdings Inc. (FTRE), Cullinan Management (CGEM) - The Globe and Mail
Compass Therapeutics (CMPX) Breaks Above Support: What’s Driving the 4.6% MoveStrangle Setup - newsline.com
CMPX Q1 2026 Earnings: Narrowed Loss Beats Estimates, Stock Surges 7.25%Forward Guidance Trends - newsline.com
CCORF Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Compass Therapeutics reports phase 1 data for CTX-8371 By Investing.com - Investing.com South Africa
Compass Therapeutics reports phase 1 data for CTX-8371 - Investing.com UK
1.21%
3.14%
자본화:
|
볼륨(24시간):